Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10374 Phase 1 in healthy subjects
NCT06033742Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing HS-10374 with Placebo (2 arms). Primary endpoints: Adverse events, Number of participants with clinical laboratory abnormalities and 3 more. Started Nov 2021; status: completed.
02
Drugs
HS-10374
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06033742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033742.